Siemens to Emphasize Emerging Fields of Oncology, Neurology Biomarkers with New Research Facility
Complete the form below to unlock access to ALL audio articles.
Siemens Medical Solutions has opened the doors to a new research facility dedicated exclusively to the development of molecular imaging biomarkers, which will become in vivo diagnostic tools for identifying debilitating diseases such as cancer, and neurological diseases at their earliest stages.
The opening of the Siemens Medical Solutions Molecular Imaging (MI) Biomarker Research facility is the latest step for the company in becoming the world’s first full-service diagnostics company, integrating in vivo and in vitro imaging diagnostics capabilities.
Siemens recently launched Siemens Medical Solutions Diagnostics as the in vitro complement to the portfolio on the heels of acquisitions of Bayer Diagnostics and Los Angeles-based Diagnostic Products Corporation.
“Molecular medicine is heralding a new era in diagnostic capabilities that could change the lives of millions of Americans – and Siemens is helping lead the field out of the research lab and into practical use,” said Michael Reitermann, president, Molecular Imaging division, Siemens Medical Solutions.
“Advancing this field brings with it the promise of personalized therapeutics, which would not only improve the efficiency of health care, but most importantly, would also improve the quality of health care for patients.”
Siemens Medical Solutions MI Biomarker Research facility will be dedicated solely to the discovery and development of new imaging biomarkers to spur the growth of in vivo molecular diagnostics.
Imaging biomarkers are molecules that are specifically designed to seek out disease indicators that may appear in individual cells or tissue in the organism and that may provide early warning signs of disease. Once these imaging biomarkers bind to the diseased cells or tissues, they cause them to “light up” when scanned using PET•CT (Positron Emission Tomography•Computed Tomography) or SPECT•CT (Single-Photon Emission Computed Tomography).
Imaging biomarkers will enable early diagnosis and measurement of how well certain therapies, such as prescription drugs, chemotherapy and radiation therapy, may be working by measuring the impact of treatments on the disease indicators. This may aid the development of new therapies, and can enable clinicians to non-invasively assess therapeutic success and quickly adjust therapeutic approaches to arrive at optimum outcomes.
The new Siemens’ facility will be led by Hartmuth Kolb, Ph.D, vice president, Siemens Medical Solutions MI Biomarker Research. The facility will house scientists, dedicated to the discovery of new imaging agents and their clinical development, with the goal of bringing several new agents to the market over the next 5 - 10 years.
Research and development efforts conducted at the facility will focus largely on oncology and neurology, and also include other areas such as inflammation and microfluidics/nanotechnology research.
The facility features the latest technology in molecular medicine applied across its research portfolio, including the facility’s discovery chemistry lab, in vitro biology lab, preclinical imaging lab, clean room for microfluidics research, instrument room for microfluidics development and a PET radiochemistry lab.
In addition to continued work on the new research imaging agent to aid in Alzheimer’s detection, the Siemens Medical Solutions MI Biomarker Research team has a number of oncology-related compounds in the discovery and translational research pipeline, which are moving towards clinical development.
In collaboration with academia and industry, molecular imaging tracers for cell proliferation (imaging of aggressive tumors), hypoxia (to aid the planning of radiation therapy), and angiogenesis (to aid chemotherapy) are currently being developed. Future research will branch out into neurology and cardiovascular disease areas.
